Last reviewed · How we verify

NCT04127058

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Completed Phase 1 Last updated 13 April 2020
What this trial tests

Phase 1 trial testing Iloperidone in Bipolar I Disorder in 12 participants. Completed in 27 November 2019.

Timeline
7 October 2019
Primary endpoint
27 November 2019
27 November 2019

Quick facts

Lead sponsorVanda Pharmaceuticals
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment12
Start date7 October 2019
Primary completion27 November 2019
Estimated completion27 November 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Vanda Pharmaceuticals — full company profile →

Who can join

Adults 18 to 65, any sex, with Bipolar I Disorder or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Iloperidone

Trials testing the same drug.

Other recruiting trials for Bipolar I Disorder

Currently open trials in the same condition.

Other Vanda Pharmaceuticals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04127058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing